No. 19-1103
INO Therapeutics LLC, et al. v. Praxair Distribution Inc., et al.
Response Waived
Experienced Counsel
Tags: 35-usc-101 drug-administration due-process eligibility innovation medical-research medical-treatment method-of-treatment patent patent-eligibility patient-outcomes personalized-medicine section-101 selective-treatment
Key Terms:
Patent JusticiabilityDoctri
Patent JusticiabilityDoctri
Latest Conference:
2020-04-03
Question Presented (AI Summary)
Whether a method of treatment that requires doctors to selectively administer a drug to certain patients and not others to enhance patient outcomes is eligible for patent protection under Section 101 of the Patent Act
Question Presented (OCR Extract)
QUESTION PRESENTED Whether a method of treatment that requires doctors to selectively administer a drug to certain patients and not others to enhance patient outcomes is eligible for patent protection under Section 101 of the Patent Act. @
Docket Entries
2020-04-06
Petition DENIED.
2020-03-18
DISTRIBUTED for Conference of 4/3/2020.
2020-03-10
Waiver of right of respondent Praxair Distribution Inc.; Praxair Inc. to respond filed.
2020-03-06
Petition for a writ of certiorari filed. (Response due April 9, 2020)
2020-01-31
Application (19A859) granted by The Chief Justice extending the time to file until March 6, 2020.
2020-01-28
Application (19A859) to extend the time to file a petition for a writ of certiorari from February 17, 2020 to March 6, 2020, submitted to The Chief Justice.
Attorneys
INO Therapeutics LLC, Mallinckrodt Hospital Products Inc., and Mallinckrodt Hospital Products IP Ltd.
Seth P. Waxman — Wilmer Cutler Pickering Hale and Dorr LLP, Petitioner
Praxair Distribution Inc.; Praxair Inc.
William Robert Peterson — Morgan, Lewis & Bockius LLP, Respondent